Transitory Growth Hormone Deficiency Successfully Treated With Human Growth Hormone

Trygstad, O

doi:10.1530/acta.0.0840011

Cited by 31 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparable findings in single cases had been reported already in 1971 and 1972 [63,192]. Later Trygstad [296] and Kastrup et al [130] described the normalisation of previously insufficient GH-increases in the ITT after longterm treatment with GH and--which was probably more important--onset of puberty.…”

Section: Growth Hormonementioning

confidence: 53%

“…The observation of Pierson and Deschamps [197], that growth velocity during the first 4 to 5 years of life would usually correspond to the average and fall to lower values thereafter is not confirmed by other authors. Weight gain follows the same trend as growth in height [205,206,296]. Particular leanness as claimed by Karp et al [128,129] has not been observed by other investigators [24,197].…”

Section: Clinical Aspectsmentioning

confidence: 87%

See 1 more Smart Citation

Stunted growth with more or less normal appearance

et al. 1982

View full text Add to dashboard Cite

Section: Growth Hormonementioning

confidence: 53%

Section: Clinical Aspectsmentioning

confidence: 87%

Stunted growth with more or less normal appearance

et al. 1982

View full text Add to dashboard Cite

“…It has been recognised for many years that children with constitutional delay of growth and puberty (CDGP) show a transient hGH suppression which has led several clinicians to use hGH in their treatment [30][31][32], These children were generally started on treatment with a diag nosis of hGH deficiency based on lack of response to pharmacological tests and their height velocities in creased, even on low doses of hGH (8-12 U/week). A decrease in physiological hGH secretion has been shown to occur in CDGP which continues up to pubertal stage 3 [33].…”

Section: Constitutional Delay Of Growth and Pubertymentioning

confidence: 99%

Non-Conventional Use of Growth Hormone: European Experience

Darendelıler

Hindmarsh²,

Brook³

1990

Horm Res

View full text Add to dashboard Cite

Results from several centres in Europe using biosynthetic human growth hormone (hGH) for the promotion of growth in a variety of conditions other than classical hGH deficiency were evaluated. Significant increments in growth rates were achieved by daily administration of hGH in doses appropriate for body size without disproportionate skeletal advances in short normals, Turner syndrome, low birth weight, skeletal dysplasia, central precocious puberty (reared with gonadotrophin-releasing hormone analogue) and renal failure.

show abstract

“…However, insufficient numbers of patients, different therapy durations, and changes in the time of the dosage prescribed, due, in particular, to a greater availability of the hormone, have led to different results (10,11). In addition, the modifications recently made in the therapy schedule and administration route, as well as the uncertainties of the diagnostic criteria indicating the subjects to be treated (13)(14)(15)(16)(17)(18)(19)(20)(21), will probably further change the final results of the treatment. It is certain, however, that the experience acquired to date has not enabled us to adopt an optimal therapeutic approach, either for the single patient or for the whole group, casting doubt on the auxological outcome of the patients treated.…”

Section: Introductionmentioning

confidence: 99%

Final height of patients treated for isolated GH deficiency: examination of 83 patients

Cacciari

Cicognani

Pirazzoli

et al. 1997

European Journal of Endocrinology

View full text Add to dashboard Cite

The aim of the present study was to evaluate retrospectively the influence of various auxological and laboratory parameters on final height in a group of GH-deficient children after replacement therapy and to compare their final height with that of a group of short children with normal GH secretion and hence not treated.The final height was evaluated of 83 patients (51 males and 32 females) affected by idiopathic isolated GH deficiency and treated with recombinant human GH (hGH) for 2-7 years. Inclusion criteria at the start of treatment were short stature (mean height for chronological age in standard deviation score (SDS) ¹2.21) due to idiopathic isolated GH deficiency (GH peak <8 mg/l after two pharmacological tests and/or mean GH concentration <3.3 mg/l during the night) and treatment with recombinant hGH for at least 2 years at a dose of 15-20 U/m 2 per week by s.c. injection for 6 or 7 days/ week. Mean chronological age at diagnosis was 12.2 Ϯ 1.7 years; 35 were prepubertal and 48 pubertal. The final height of 51 untreated short stature (mean height for chronological age in SDS ¹2.13 at diagnosis) subjects (42 males and 9 females; 29 prepubertal and 22 pubertal at diagnosis with mean chronological age 11.6 Ϯ 2.4 years) with normal GH secretion was also evaluated.In the treated subjects final height SDS was higher than that of the untreated group (¹1.3 vs ¹1.7 SDS; P ¼ 0.01). Both treated and untreated subjects showed a final height lower than target height, but 39% of the treated subjects vs only 20% of the untreated group (P ¼ 0.035) had a final height greater than target height. In the treated subjects this percentage was higher in the patients improving their height for bone age in the first years of therapy. While treated females showed a positive correlation only between target and final height (P ¼ 0.0001), in treated males final height correlated with the Bayley-Pinneau prediction at diagnosis, height for chronological age and bone age at diagnosis and target height. Patients who started therapy before puberty also showed these correlations with data calculated at the onset of puberty, together with a correlation with chronological age at the onset of puberty.When considering the influence of GH response at tests on final height, the percentage of subjects exceeding target height increased progressively according to the severity of the GH deficiency. There was no difference in height gain between the patients starting therapy before or during puberty. The height gain, however modest, obtained by our treated patients, the number of patients with final height greater than target height and the favourable comparison with the untreated short-stature subjects represent a promising result, which could be improved by personalizing treatment. European Journal of Endocrinology 137 53-60

show abstract

Transitory Growth Hormone Deficiency Successfully Treated With Human Growth Hormone

Cited by 31 publications

References 10 publications

Stunted growth with more or less normal appearance

Stunted growth with more or less normal appearance

Non-Conventional Use of Growth Hormone: European Experience

Final height of patients treated for isolated GH deficiency: examination of 83 patients

Contact Info

Product

Resources

About